Comparative Pharmacology
Head-to-head clinical analysis: FLEXERIL versus ZANAFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLEXERIL versus ZANAFLEX.
FLEXERIL vs ZANAFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from CNS, leading to decreased muscle tone and spasticity.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Initial: 2 mg orally every 6-8 hours as needed, up to 3 times daily. Maximum: 36 mg per day.
None Documented
None Documented
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Terminal elimination half-life is approximately 2.5 hours in healthy adults; clinically, this short half-life necessitates multiple daily dosing for sustained effect and contributes to its use as needed for spasticity.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Approximately 95% of a dose is eliminated via hepatic metabolism; renal excretion accounts for about 20% as unchanged drug and metabolites, with about 20% eliminated in feces.
Category C
Category C
Muscle Relaxant
Muscle Relaxant